Trials In Focus: Diverse Enrollment Lagging In Oncology, IQVIA Finds
Also, CRO Syneos Health appointed an executive to its newly created DE&I position, while Alterity started a new Phase II study in multiple system atrophy, Antabio dosed the first patients in its Phase I study of an antibiotic for hospital infections, and Structure Therapeutics started a Phase IIa trial of its GLP-1 agonist in obesity and diabetes, with plans for a Phase IIb trial in 2024.
You may also be interested in...
Rick Pazdur's wish for the National Cancer Institute to help industry speed US trial enrollment and diversity could get a boost if Congress fulfills Biden’s new fiscal year Cancer Moonshot funding request.
The AUGMENT-101 study showed a strong response rate among acute leukemia patients who historically have a poor prognosis.
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.